Eikelboom JW - Search Results

1

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators. Connolly SJ, et al. Among authors: eikelboom jw. Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10. Lancet. 2018. PMID: 29132879 Clinical Trial.

2

Low rates of preventive practices in patients with peripheral vascular disease.

Anand SS, Kundi A, Eikelboom J, Yusuf S. Anand SS, et al. Can J Cardiol. 1999 Nov;15(11):1259-63. Can J Cardiol. 1999. PMID: 10579741

3

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.

Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Eikelboom JW, et al. Circulation. 2002 Apr 9;105(14):1650-5. doi: 10.1161/01.cir.0000013777.21160.07. Circulation. 2002. PMID: 11940542

4

Antiplatelet agents in acute coronary syndromes.

Eikelboom JW, Anand S. Eikelboom JW, et al. Semin Vasc Med. 2003 Nov;3(4):403-14. doi: 10.1055/s-2004-817689. Semin Vasc Med. 2003. PMID: 15199447 Review.

5

Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes.

Mehta SR, Eikelboom JW, Demers C, Maggioni AP, Commerford PJ, Yusuf S. Mehta SR, et al. Among authors: eikelboom jw. Can J Physiol Pharmacol. 2005 Jan;83(1):98-103. doi: 10.1139/y05-003. Can J Physiol Pharmacol. 2005. PMID: 15759056 Clinical Trial.

6

Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.

Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Eikelboom JW, et al. Circulation. 2005 Dec 20;112(25):3855-67. doi: 10.1161/CIRCULATIONAHA.105.573550. Epub 2005 Dec 12. Circulation. 2005. PMID: 16344381

7

Aspirin resistance.

Hankey GJ, Eikelboom JW. Hankey GJ, et al. Among authors: eikelboom jw. Lancet. 2006 Feb 18;367(9510):606-17. doi: 10.1016/S0140-6736(06)68040-9. Lancet. 2006. PMID: 16488805 Review.

8

ESPRIT trial.

O'Donnell M, Eikelboom JW. O'Donnell M, et al. Among authors: eikelboom jw. Lancet. 2006 Aug 5;368(9534):447; author reply 449. doi: 10.1016/S0140-6736(06)69144-7. Lancet. 2006. PMID: 16890824 No abstract available.

9

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Eikelboom JW, et al. Circulation. 2006 Aug 22;114(8):774-82. doi: 10.1161/CIRCULATIONAHA.106.612812. Epub 2006 Aug 14. Circulation. 2006. PMID: 16908769

10

Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction.

Eikelboom JW, O'Donnell M. Eikelboom JW, et al. JAMA. 2007 Jan 3;297(1):91-2. doi: 10.1001/jama.297.1.91. JAMA. 2007. PMID: 17200480 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

590 results

Search Page